{
    "id": "5da940bc-28c3-4e0c-ac51-912f8cc1beb1",
    "indications": {
        "text": "avycaz combination ceftazidime , cephalosporin , avibactam , beta-lactamase inhibitor , indicated treatment following infections caused designated susceptible gram-negative microorganisms adult pediatric patients ( least 31 weeks gestational age ) : complicated intra-abdominal infections ( ciai ) , used combination metronidazole ( 1.1 ) complicated urinary tract infections ( cuti ) , including pyelonephritis ( 1.2 ) hospital-acquired bacterial pneumonia ventilator-associated bacterial pneumonia ( habp/vabp ) ( 1.3 ) reduce development drug-resistant bacteria maintain effectiveness avycaz antibacterial drugs , avycaz used treat prevent infections proven strongly suspected caused susceptible bacteria . ( 1.4 )",
        "doid_entities": [
            {
                "text": "pyelonephritis (DOID:11400)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11400"
            },
            {
                "text": "bacterial pneumonia (DOID:874)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_874"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "avycaz adult patients creatinine clearance ( crcl ) greater 50 ml/min ( 2.1 ) infection dose frequency infusion time ciai * , cuti including pyelonephritis , habp/vabp avycaz 2.5 grams ( ceftazidime 2 grams avibactam 0.5 grams ) every 8 hours 2 hours * used conjunction metronidazole 0.5 g intravenously every 8 hours adult ciai patients avycaz pediatric patients aged 2 years less 18 years estimated glomerular filtration rate ( egfr ) greater 50 ml/min/1.73 2 pediatric patients less 2 years age without renal impairment ( 2.2 ) infection age range dose infusion time/ frequency ciai * , cuti including pyelonephritis , habp/vabp 2 years less 18 years avycaz 62.5 mg/kg maximum 2.5 grams ( ceftazidime 50 mg/kg avibactam 12.5 mg/kg maximum dose ceftazidime 2 grams avibactam 0.5 grams ) 2 hours/ every 8 hours 6 months less 2 years avycaz 62.5 mg/kg ( ceftazidime 50 mg/kg avibactam 12.5 mg/kg ) 3 months less 6 months avycaz 50 mg/kg ( ceftazidime 40 mg/kg avibactam 10 mg/kg ) greater 28 days less 3 months avycaz 37.5 mg/kg ( ceftazidime 30 mg/kg avibactam 7.5 mg/kg ) less equal 28 days b ga 31 weeks older avycaz 25 mg/kg ( ceftazidime 20 mg/kg avibactam 5 mg/kg ) * used conjunction metronidazole 10 mg/kg intravenously every 8 hours pediatric ciai patients includes full-term infants pna > 28 days pre-term infants corrected age > 28 days . corrected age calculated subtracting number weeks born 40 weeks gestation postnatal age . b includes neonates pna \u2264 28 days pre-term infants corrected age \u2264 28 days . ga = gestational age pna = postnatal age . treatment ciai , metronidazole given concurrently recommended duration treatment adult pediatric patients : ( 2.1 , 2.2 ) ciai : 5 14 days cuti including pyelonephritis : 7 14 days habp/vabp : 7 14 days adjustment required adult patients creatinine clearance ( crcl ) less equal 50 ml/min pediatric patients aged 2 years older renal impairment . insufficient information recommend dosing regimen pediatric patients younger 2 years age renal impairment . full prescribing information additional information . ( 2.3 ) full prescribing information instructions constituting supplied dry powder subsequent required dilution . ( 2.4 ) full prescribing information compatibilities . ( 2.5 )",
        "doid_entities": [
            {
                "text": "pyelonephritis (DOID:11400)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11400"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "avycaz 2.5 grams ( ceftazidime avibactam ) injection supplied white yellow sterile powder constitution single-dose , clear glass vial containing : ceftazidime 2 grams avibactam 0.5 grams . vials supplied individual vial ( ndc # 0456-2700-01 ) cartons containing 10 vials ( ndc # 0456-2700-10 ) . avycaz vials stored 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect light . store carton time . storage conditions constituted diluted solutions avycaz injection described another section labeling [ ( 2.4 , 2.6 ) ] .",
    "adverseReactions": "avycaz contraindicated patients known serious hypersensitivity components avycaz ( ceftazidime avibactam ) , avibactam containing products , members cephalosporin class [ ( 5.2 ) ] .",
    "ingredients": [
        {
            "name": "CEFTAZIDIME",
            "code": "9M416Z9QNR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3508"
        },
        {
            "name": "AVIBACTAM SODIUM",
            "code": "9V824P8TAI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85982"
        },
        {
            "name": "SODIUM CARBONATE",
            "code": "45P3261C7T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29377"
        }
    ],
    "organization": "Allergan, Inc.",
    "name": "AVYCAZ",
    "effectiveTime": "20250425",
    "indications_original": "AVYCAZ is a combination\u00a0of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor,\u00a0indicated for\u00a0the treatment of the following infections caused by designated susceptible\u00a0Gram-negative microorganisms in\u00a0adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis\u00a0( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by\u00a0susceptible\u00a0bacteria.\u00a0( 1.4 )",
    "contraindications_original": "Dosage of AVYCAZ in Adult Patients with Creatinine Clearance ( CrCl ) greater than 50 mL/min ( 2.1 ) Infection Dose Frequency Infusion Time cIAI * , cUTI including Pyelonephritis, and HABP/VABP AVYCAZ 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) Every 8 hours 2 hours * Used in conjunction with metronidazole 0.5 g intravenously every 8 hours in adult cIAI patients Dosage of AVYCAZ in Pediatric Patients aged 2 years to less than 18 years with Estimated Glomerular Filtration Rate (eGFR) greater than 50\u00a0mL/min/1.73 m 2 and in Pediatric Patients less than 2 years of age without Renal Impairment ( 2.2 ) Infection Age Range Dose Infusion Time/\u00a0Frequency cIAI * , cUTI including Pyelonephritis, HABP/VABP 2 years to less than 18\u00a0years AVYCAZ 62.5 mg/kg to a maximum of 2.5 grams (ceftazidime 50 mg/kg and avibactam 12.5 mg/kg to a maximum dose of ceftazidime 2 grams and avibactam 0.5 grams) 2 hours/ Every 8 hours 6 months to less than 2\u00a0years AVYCAZ 62.5 mg/kg (ceftazidime 50 mg/kg and avibactam 12.5\u00a0mg/kg) 3 months to less than 6\u00a0months AVYCAZ 50 mg/kg (ceftazidime 40 mg/kg and avibactam 10 mg/kg) Greater than 28 days a to less than 3 months AVYCAZ 37.5 mg/kg (ceftazidime 30 mg/kg and avibactam 7.5 mg/kg) Less than or equal to 28 days b with GA 31 weeks and older AVYCAZ 25 mg/kg (ceftazidime 20 mg/kg and avibactam 5 mg/kg) * Used in conjunction with metronidazole 10 mg/kg intravenously every 8\u00a0hours in pediatric cIAI patients a Includes full-term infants with PNA > 28 days and pre-term infants with corrected age > 28 days. Corrected age is calculated by subtracting the number of weeks born before 40 weeks of gestation from the postnatal age. b Includes neonates PNA \u2264 28 days and pre-term infants with corrected age \u2264 28 days. GA = gestational age and PNA = postnatal age. For treatment of cIAI, metronidazole should be given concurrently Recommended duration of treatment in adult and pediatric patients: ( 2.1 , 2.2 ) cIAI: 5 to 14 days cUTI including pyelonephritis: 7 to 14 days HABP/VABP: 7 to 14 days Dosage adjustment is required\u00a0in adult patients with creatinine clearance (CrCl) less than or equal to\u00a050 mL/min and in pediatric patients aged 2 years and older with renal impairment. There is insufficient information to recommend a dosing regimen for pediatric patients younger than 2 years of age with renal impairment. See Full Prescribing Information for additional information. ( 2.3 ) See Full Prescribing Information for instructions for constituting supplied dry powder and subsequent required dilution. ( 2.4 ) See Full Prescribing Information for drug compatibilities. ( 2.5 )",
    "warningsAndPrecautions_original": "AVYCAZ 2.5 grams (ceftazidime and avibactam) for injection is supplied as a white to yellow sterile powder for constitution in single-dose, clear glass vial containing: ceftazidime\u00a02 grams and avibactam\u00a00.5 grams. Vials are supplied as\u00a0individual vial (NDC#\n                     \u00a00456-2700-01) and in cartons containing 10 vials (NDC# 0456-2700-10).\n                  AVYCAZ vials should be stored at 25\u00b0C (77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [See USP Controlled Room Temperature]. Protect from light. Store in carton until time of use.\n                  Storage conditions for constituted and diluted solutions of AVYCAZ for injection are described in another section of labeling [see Dosage and Administration (\n                     \n                        2.4\n                     , \n                        2.6\n                     \n                     )].",
    "adverseReactions_original": "AVYCAZ\u00a0is contraindicated in patients with known serious hypersensitivity to the components of\u00a0AVYCAZ (ceftazidime and avibactam),\u00a0avibactam\u00a0containing products, or other members of the cephalosporin class\u00a0[see Warnings and Precautions (\n                     \n                        5.2\n                     \n                     )]\n                     .",
    "drug": [
        {
            "name": "AVYCAZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85989"
        }
    ]
}